Inclusion Criteria:

- Postmenopausal females

- Histologically or cytologically confirmed diagnosis of breast carcinoma

- Locally advanced or locally recurrent inoperable or metastatic breast carcinoma with
documented disease progression

- Has laboratory documentation of positive estrogen receptor (ER) and/or progesterone
receptor (PgR) status, and has responded to the standard first or second line
hormonal anti-tumor therapy given

- Has received and whose disease progressed after one or two prior systemic hormonal
anti-tumor therapies

- Performance status of greater than or equal to 2 on the Zubrod scale

- Predicted life expectancy of greater than or equal to 12 weeks

- Must give written informed consent

- Measurable disease according to the Response Evaluation Criteria in Solid Tumors
(RECIST) criteria

- Absolute granulocyte count of greater than 1,500/meqL, platelet count greater than
75,000/meqL, and a hemoglobin of greater than 10 g/dL

- Adequate liver and renal function as defined by a bilirubin of less than 1.5 times
the upper limit of normal and a creatinine of less than 1.5 times the upper limit of
normal

- Transaminases must be less than 2.5 times the upper limit of normal except for
patients with liver metastases who may have transaminases less than 5 times the upper
limit of normal.

- The patient has recovered from all previous anti-cancer treatment related to
toxicities to at least Grade 1.

- All previous investigational drugs must be stopped at least four weeks before
commencement of treatment with TAS-108.